{"schema_version":"secwatch.filing_event.v1","accession":"0000719135-24-000005","form_type":"8-K","ticker":"APYX","cik":"0000719135","company_name":"Apyx Medical Corp","filed_at":"2024-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.742835+00:00","generated_at":"2026-06-06T20:50:25.936921+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Apyx Medical publishes 483-patient study showing Renuvion safety after liposuction across multiple body areas","bullets":["Analysis of 483 patients (1,184 body areas) found no new or increased risks vs. liposuction alone.","Peer-reviewed publication in Aesthetic Surgery Journal Open Forum; data previously used for FDA 510(k) clearance in 2023.","CEO states evidence strengthens clinical portfolio for Renuvion; no alternative FDA-cleared therapy exists for the indication."],"urls":{"canonical":"https://secwatch.observer/filing/0000719135-24-000005","json":"https://secwatch.observer/filing/0000719135-24-000005.json","markdown":"https://secwatch.observer/filing/0000719135-24-000005.md","text":"https://secwatch.observer/filing/0000719135-24-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000005/0000719135-24-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000005/apyx-20240122.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T20:50:25.936921+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}